Lack of relationship between EGFR-1 immunohistochemical expression and prognosis in a multicentre clinical trial of 93 patients with advanced primary ovarian epithelial cancer (GINECO group)
| Autor: | A Le Tourneau, Josée Audouin, Eric Pujade-Lauraine, Philippe Broët, L Chauvenet, J F Geay, V Girre, Mohib Morcos, Béatrice Marmey, Sophie Camilleri-Broët, C Elie |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Adult
Oncology Cancer Research medicine.medical_specialty Pathology EGFR-1 medicine.medical_treatment Disease-Free Survival Targeted therapy Clinical Predictive Value of Tests Internal medicine Ovarian carcinoma Antineoplastic Combined Chemotherapy Protocols medicine Humans Epidermal growth factor receptor Aged Retrospective Studies Ovarian Neoplasms biology business.industry Anatomical pathology Combination chemotherapy Middle Aged Prognosis medicine.disease Immunohistochemistry ovarian carcinoma ErbB Receptors Disease Progression biology.protein Female Ovarian cancer business Immunostaining |
| Zdroj: | British Journal of Cancer |
| ISSN: | 1532-1827 0007-0920 |
| DOI: | 10.1038/sj.bjc.6601961 |
| Popis: | Epidermal growth factor receptor 1 (EGFR-1) overexpression is usually described as linked with a worse prognosis in a variety of tumours of epithelial origin. However, its role in ovarian cancer is still controversial. The aim of the present study was to analyse the prognostic impact of EGFR-1 in a retrospective series of 93 stage III-IV primary ovarian epithelial tumours. All patients, enrolled in a multicentre GINECO prospective clinical trial, were treated with the same platinum-based combination chemotherapy, and were followed up with a median of 69 months. Epidermal growth factor receptor 1 plasma membrane expression, assessed by immunohistochemistry on paraffin-embedded tissues, was correlated with clinical parameters as well as immunohistochemical expression results of HER-2 (c-erbB-2), BAX, BCL-2, p53 and anti-Ki-67, previously studied in the same series of patients. Positive immunostaining for EGFR-1 was seen in 31 of the 93 analysed cases (33%). No correlation was found between EGFR-1 expression and clinical parameters. No correlation was found between EGFR-1 expression and other biological markers, except for HER-2, which was limit for significance. Indeed, among the EGFR-1-negative cases, 10.3% expressed HER-2, whereas the HER-2-expressing tumours accounted for 27.6% of EGFR-1-positive cases (P=0.06). Epidermal growth factor receptor 1 overexpression had no prognostic impact on both overall and progression-free survival through univariate and multivariate analyses. The potential effect of EGFR-1 and HER-2 co-expression on targeted therapy against EGFR-1 and/or HER-2 molecules has to be further analysed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|